CAMBRIDGE, Mass., March 27, 2017 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ: BPMC), a leader in discovering
and developing targeted kinase medicines for patients with
genomically defined diseases, today announced that it will present
on the discovery and development of BLU-285 and BLU-554 at the 2017
Annual Meeting of the American Association for Cancer Research,
taking place April 1-5, 2017 in
Washington D.C., and at the
253rd American Chemical Society National Meeting &
Exposition, taking place April 2-6,
2017 in San Francisco,
CA.
Details of the presentations are as follows:
2017 Annual Meeting of the American Association for Cancer
Research
Date & Time: Sunday, April 2,
2017 at 4:36 p.m. ET –
5:00 p.m. ET
Session Title: New Drugs on the Horizon 2
Presentation Title: BLU-285: A potent and highly selective
inhibitor designed to treat malignancies driven by PDGFRα and KIT
mutations
Location: East Salon A-B, Level 1, Walter E. Washington
Convention Center
253rd American Chemical Society National Meeting
& Exposition
Date & Time: Wednesday, April
5, 2017 – 10:00 a.m. PT –
10:30 a.m. PT
Division Title: Division of Medicinal Chemistry
Session Title: First Time Disclosures
Paper ID: 2656485
Paper Title: Discovery and development of BLU-554: A potent,
highly selective covalent inhibitor of Fibroblast Growth Factor
Receptor 4 (FGFR4) in development for the targeted treatment of
advanced Hepatocellular Carcinoma (HCC) patients with amplified and
overexpressed FGF19
Location: 3002/3004 - Moscone Convention Center
Date & Time: Wednesday, April
5, 2017 – 3:30 p.m. PT –
4:00 p.m. PT
Division Title: Division of Medicinal Chemistry
Session Title: First Time Disclosures
Paper ID: 2656892
Paper Title: Discovery and development of BLU-285: A potent,
highly selective inhibitor of KIT and PDGFRα activation loop
mutants
Location: 3002/3004 - Moscone Convention Center
Abstracts from presentations at the 253rd American
Chemical Society National Meeting & Exposition are available
online on the conference website at:
https://www.acs.org/content/acs/en/meetings/spring-2017.html.
About Blueprint Medicines
Blueprint Medicines is developing a new generation of
targeted and potent kinase medicines to improve the lives of
patients with genomically defined diseases. Its approach is rooted
in a deep understanding of the genetic blueprint of cancer and
other diseases driven by the abnormal activation of
kinases. Blueprint Medicines is advancing four programs
in clinical development for subsets of patients with
gastrointestinal stromal tumors, hepatocellular carcinoma, systemic
mastocytosis, non-small cell lung cancer, medullary thyroid cancer
and other advanced solid tumors, as well as multiple programs in
research and preclinical development.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-on-blu-285-and-blu-554-at-upcoming-scientific-conferences-300429766.html
SOURCE Blueprint Medicines Corporation